Olaparib (Lynparza) has been granted an orphan drug designation by the FDA for the treatment of patients with pancreatic cancer, AstraZeneca and Merck, the developers of the PARP inhibitor, have announced.
Roy Baynes, MD, PhD
Roy Baynes, MD, PhD
Olaparib (Lynparza) has been granted an orphan drug designation by the FDA for the treatment of patients with pancreatic cancer, AstraZeneca and Merck, the developers of the PARP inhibitor, have announced.1
The ongoing, randomized, multicenter, double-blind, placebo-controlled phase III POLO trial (NCT02184195) is currently evaluating olaparib as maintenance therapy in patients with germlineBRCA1/2-mutated metastatic pancreatic cancer whose disease has not progressed following first-line platinum-based chemotherapy.
A total 145 patients have been randomized 3:2 to receive oral olaparib tablets at 300 mg twice daily as maintenance therapy versus placebo also twice daily. Randomization occurs within 6 weeks following last chemotherapy dose and olaparib/placebo treatment will begin within 4 to 8 weeks of the last chemotherapy dose. Following randomization, patients have weekly clinical visits for the first 4 weeks of treatment, then every 4 weeks while on study treatment.
Treatment will continue until objective radiological disease progression. Following progression, patients will be followed for second progression every 8 weeks, and then for survival until final analysis.
Eligible patients were previously treated for metastatic disease and have not progressed following completion of at least 16 weeks of frontline platinum-based chemotherapy. Additionally, patients must have a known deleterious or suspected deleterious germlineBRCAmutation. Those who were previously treated with a PARP inhibitor were excluded.
The primary endpoint is progression-free survival. Secondary endpoints are overall survival, time from randomization to second progression or death, objective response rate, disease control rate, safety, and tolerability. Results from this study are expected in the first half of 2019.
“The FDA granting orphan drug designation is a positive step for patients with pancreatic cancer and continues to reinforce the importance of our collaboration in bringing Lynparza to more patients in need,” said Roy Baynes, senior vice president and head of global clinical development, chief medical officer, at Merck Research Laboratories.
AstraZeneca and Merck announced a global strategic oncology collaboration to develop and commercialize olaparib, as well as the MEK inhibitor selumetinib, for multiple cancer types in July 2017.
The FDA grants orphan drug designation status to medicines intended for the treatment, diagnosis, or prevention of rare diseases or disorders that affect fewer than 200,000 people in the United States. Pancreatic cancer accounts for approximately 3% of all U.S. cancers and 5-year survival rates remain at 8.5%, AstraZeneca stated in a news release.
“Pancreatic cancer is an area of significant unmet medical need,” said Sean Bohen, executive vice president, global medicines development, and chief medical officer at AstraZeneca. “This is especially true for patients with metastatic disease, where the benefits of current treatment options are very limited.”
This is the fourth time the FDA has designated olaparib as an orphan drug, the first coming in 2013 for the treatment of patients with ovarian cancer. In August 2017, the FDA expanded approval of olaparib tablets as a maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, who are in a complete or partial response to platinum-based chemotherapy regardless ofBRCAstatus based on data from the phase III SOLO2 and the phase II Study 19 trials. In 2018, the agency granted an amended orphan drug status to include both fallopian tube and primary peritoneal cancers.
In SOLO2, maintenance treatment with olaparib showed a 70% reduction in the risk of progression or death compared with placebo for patients with platinum-sensitive, relapsed,BRCA-mutant ovarian cancer.2 In Study 19, the risk of progression or death was reduced by 65% with maintenance olaparib versus placebo for women with ovarian cancer, regardless ofBRCAstatus.3